Thea Pharma

Thea Pharma

MA - Waltham
Pharmaceutical
WebsiteLinkedInCareers Page

Focus: Ophthalmic Therapies

Thea Pharma is a life sciences company focused on Ophthalmic Therapies.

Ophthalmology
Funding Stage
PUBLIC
Open Jobs
0

Products & Portfolio (7)

1 discontinued product not shown

AKTEN
lidocaine hydrochloride anhydrous
LOE Approaching
OPHTHALMIC · GEL
impulses, thereby effecting local anesthetic action. Anesthesia generally occurs between 20 seconds to 1 minute and persists for 5 to 30 minutes.
2008
25
AZASITE
azithromycin monohydrate
LOE Approaching
OPHTHALMIC · SOLUTION/DROPS
12.1 Mechanism of Action Azithromycin is a macrolide antibiotic [see ] . 12.3 Pharmacokinetics The plasma concentration of azithromycin following ocular administration of AzaSite (azithromycin ophthalmic solution) in humans is unknown. Based on the proposed dose of one drop to each eye (total dose of 100 mcL or 1 mg) and exposure information from systemic administration, the systemic concentration of azithromycin following ocular administration is estimated to be below quantifiable limits (≤10 ng/mL) at steady-state in humans, assuming 100% systemic availability. 12.4 Microbiology Azithromycin acts by binding to the 50S ribosomal subunit of susceptible microorganisms and interfering with microbial protein synthesis. Azithromycin has been shown to be active against most isolates of the following microorganisms, both in vitro and clinically in conjunctival infections [see ] . CDC coryneform group G Efficacy for this organism was studied in fewer than 10 infections. Haemophilus influenzae Staphylococcus aureus Streptococcus mitis group Streptococcus pneumoniae The following in vitro data are also available, but their clinical significance in ophthalmic infections is unknown. The safety and effectiveness of AzaSite in treating ophthalmological infections due to these microorganisms have not been established. The following microorganisms are considered susceptible when evaluated using systemic breakpoints. However, a correlation between the in vitro systemic breakpoint and ophthalmological efficacy has not been established. This list of microorganisms is provided as an aid only in assessing the potential treatment of conjunctival infections. Azithromycin exhibits in vitro minimal inhibitory concentrations (MICs) of equal or less (systemic susceptible breakpoint) against most (≥90%) of isolates of the following ocular pathogens: Chlamydia pneumoniae Chlamydia trachomatis Legionella pneumophila Moraxella catarrhalis Mycoplasma hominis Mycoplasma pneumoniae Neisseria gonorrhoeae Peptostreptococcus species Streptococci (Groups C, F, G) Streptococcus pyogenes Streptococcus agalactiae Ureaplasma urealyticum Viridans group streptococci
bacterial conjunctivitis caused by susceptible isolates of the following microorganisms: CDC coryneform group GHaemophilus influenzaeStaphylococcus aureus+2 more
2007
30
COSOPT
dorzolamide hydrochloride and timolol maleate
LOE Approaching
OPHTHALMIC · SOLUTION/DROPS
components: dorzolamide hydrochloride and timolol maleate. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma, by reducing aqueous humor secretion. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous field loss and optic nerve damage. Dorzolamide hydrochloride is an inhibitor of human carbonic anhydrase II. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Timolol maleate is a beta 1 and beta 2 (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. The combined effect of these two agents administered as COSOPT twice daily results in additional intraocular pressure reduction compared to either component administered alone, but the reduction is not as much as when dorzolamide administered three times daily and timolol twice daily are administered concomitantly. [see ] .
elevated intraocular pressure (IOP) in patients with open-angle glaucomaocular hypertensionhypertension+1 more
1998
30
COSOPT PF
dorzolamide hydrochloride and timolol maleate
Peak
OPHTHALMIC · SOLUTION/DROPS
components: dorzolamide hydrochloride and timolol maleate. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma, by reducing aqueous humor secretion. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous field loss and optic nerve damage. Dorzolamide hydrochloride is an inhibitor of human carbonic anhydrase II. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Timolol maleate is a beta 1 and beta 2 (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. The combined effect of these two agents administered as COSOPT PF administered twice daily results in additional intraocular pressure reduction compared to either component administered alone, but the reduction is not as much as when dorzolamide administered three times daily and timolol twice daily are administered concomitantly. [See .]
elevated intraocular pressure (IOP) in patients with open-angle glaucomaocular hypertensionhypertension+1 more
2012
30
IYUZEH
latanoprost ophthalmic solution 0.005%
Peak
OPHTHALMIC · SOLUTION/DROPS
2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
elevated intraocular pressure (IOP) in patients with open-angle glaucomaocular hypertensionelevated intraocular pressure in patients with open-angle glaucoma+1 more
2022
0
ZIOPTAN
tafluprost
Peak
OPHTHALMIC · SOLUTION/DROPS
Prostaglandin Receptor Agonists
2012
8
ZOLYMBUS
bimatoprost
Launch
OPHTHALMIC · GEL
2025
0

Pipeline & Clinical Trials

Thealoz Duo
Dry Eye Disease
N/A
Clinical Trials (1)
NCT05356728Comparison of Two Types of Artificial Tears
N/A
N/A
Clinical Trials (1)
NCT06375499Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome.
N/A
T10070, Plastic tube with a roll-on applicator filled with an ointment
Healthy Volunteers
N/A
Clinical Trials (1)
NCT05622435Clinical Investigation to Evaluate the Tolerance of T10070 on Healthy Volunteers
N/A
N/A
Clinical Trials (1)
NCT07234318Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears
N/A
N/A
Clinical Trials (1)
NCT04499820Effect of OMEGA3 Supplementation in Diabetic Retinopathy
N/A
N/A
Clinical Trials (1)
NCT02617095Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye Syndrome
N/A
N/A
Clinical Trials (1)
NCT03830359Efficacy, Safety of T2769 in Dry Eye Disease
N/A
Thealoz Duo
Dry Eye
N/A
Clinical Trials (1)
NCT04803240Survey: Evaluation of Ocular Surface Disease Symptoms and Patient Satisfaction With Thealoz® Duo After 84 Days of Daily Treatment
N/A
N/A
Clinical Trials (1)
NCT07007702Anti-inflammatory Effects and Clinical Efficacy of Topical Thealoz Total Eye Drops in Patients With Chronic Dry Eye Disease
N/A
N/A
Clinical Trials (1)
NCT04756310Study of Nutritional Supplementation in Patients With Unilateral Wet AMD
N/A
Dorsal genital nerve stimulation
Stress Urinary Incontinence
N/A
Clinical Trials (1)
NCT05804552The Effect of Dorsal Genital Nerve Stimulation on Opening Urethral Pressure
N/A
Blephademodex
Demodex Blepharitis
N/A
Clinical Trials (1)
NCT04780165Efficacy and Tolerability of Blephademodex Wipes
N/A
N/A
Clinical Trials (1)
NCT02373397Cacicol20® in Corneal Wound Healing and Nerve Regeneration After Phototherapeutic Keratectomy
N/A
N/A
Clinical Trials (1)
NCT02979054Performance and Safety Assessment of T4020 in Managing Corneal Epithelial Defect Following Epi-off Accelerated Crosslinking
N/A
N/A
Clinical Trials (1)
NCT03874429Efficacy of T2259 in DED
N/A
Preservative free hyaluronic acid artificial tear
Evaporative Dry Eye
N/A
Clinical Trials (1)
NCT05536661Impact of Tear Substitute Use on Dry Eye in Gamers.
N/A
N/A
Clinical Trials (1)
NCT04778436Macula Evolution in Patients With AMD Taking Oral Food Supplementation
N/A
N/A
Clinical Trials (1)
NCT01546012Assessment of Patient's Satisfaction Regarding the Handiness of Two Hyaluronic Acid Eye Drops Vials
N/A
Real-world Study to Assess Adherence to IOP Lowering Therapy in Glaucoma Patients Using CONNECTDROP®
Adherence to Glaucoma Therapy
N/A
Clinical Trials (1)
NCT07206628Real-world Study to Assess Adherence to IOP Lowering Therapy in Glaucoma Patients Using CONNECTDROP®
N/A
Management of Eyelid Disorders by Ophthalmologists in Usual Medical Practice
Palpebral Pathologies
N/A
Clinical Trials (1)
NCT01552174Management of Eyelid Disorders by Ophthalmologists in Usual Medical Practice
N/A
T2769
Dry Eye
N/A
Clinical Trials (1)
NCT05965778Performance and Safety of T2769 in DED
N/A
N/A
Clinical Trials (1)
NCT03739255Facilitation of Corneal Re-epithelialization After Photorefractive Keratectomy
N/A
N/A
Clinical Trials (1)
NCT04596605Gastrointestinal Tolerance Assessment of T2309
N/A
Cosmetic: Blephaderm
Eyelid; Wound
N/A
Clinical Trials (1)
NCT07234292Evaluation of Patient Satisfaction With Blephaderm as a Complementary Care in Post-eyelid Surgery.
N/A
N/A
Clinical Trials (1)
NCT04482465Omega 3 and Vitamin D Dosage in a Population With Moderate to High Risk of AMD
N/A
T2769
Dry Eye
N/A
Clinical Trials (1)
NCT05931861Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms.
N/A
Single arm
Glaucoma
N/A
Clinical Trials (1)
NCT04552964Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
N/A
Phase 1
Clinical Trials (1)
NCT00357539Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1 and 1.5% in 48 Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT00357383Study of the Ocular Safety After Repeated Instillations of T1225 1% or 1.5% Eye Drops in Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT00356850Ocular Pharmacokinetics After a Single Drop Instillation of T1225 0.5, 1, 1.5% in 91 Healthy Volunteers
Phase 1
Warming goggles
Eyelid Diseases
Phase 1
Clinical Trials (1)
NCT01190397Warming Efficiency of Warm Compresses Versus BLEPHASTEAM® in Eyelid Therapy
Phase 1
Phase 1
Clinical Trials (1)
NCT00357292Ocular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT01086943Clinical Safety Study on an Eyelid Warming Device to Evaluate the Eyelid and Cornea Temperature in Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT00356772Azithromycin Level in Tears and in Conjunctiva in 36 Healthy Volunteers
Phase 1
Bimatoprost Ophthalmic
Healthy Volunteers
Phase 1
Clinical Trials (1)
NCT05729594Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers
Phase 1
Phase 1/2
Clinical Trials (1)
NCT03140969Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Phase 1/2
Kinezodianone R hydrochloride
Glaucoma
Phase 1/2
Clinical Trials (1)
NCT05389267Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT03913130Extension Study to Study PQ-110-001 (NCT03140969)
Phase 1/2
Phase 2
Clinical Trials (1)
NCT01494753Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or Ocular Hypertension
Phase 2
Food supplement
Dry Eye Syndromes
Phase 2
Clinical Trials (1)
NCT00357201Efficacy of T1675 Versus Placebo in Patients With Bilateral Treated Moderate Dry Eye Syndrome
Phase 2
Phase 2
Clinical Trials (1)
NCT01156025Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis
Phase 2
Phase 2
Clinical Trials (1)
NCT07169695A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis
Phase 2
Intravitreal Injection of Ultevursen
Retinitis Pigmentosa (RP)
Phase 2
Clinical Trials (1)
NCT06627179Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
Phase 2
Phase 2
Clinical Trials (1)
NCT01344083Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis
Phase 2
RNA antisense oligonucleotide for intravitreal injection
Retinitis Pigmentosa
Phase 2
Clinical Trials (1)
NCT05085964An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
Phase 2
T4090 0.2%
Glaucoma
Phase 2
Clinical Trials (1)
NCT06394973Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
Phase 2
Azithromycin
Blepharitis
Phase 2
Clinical Trials (1)
NCT01089608Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis
Phase 2
Phase 2/3
Clinical Trials (1)
NCT05158296Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
Phase 2/3
Phase 2/3
Clinical Trials (1)
NCT05176717Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)
Phase 2/3
Phase 3
Clinical Trials (1)
NCT01156012Efficacy and Safety Assessment of T2345 in Ocular Hypertensive or Glaucomatous Patients
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 2019
Portfolio: 8 approved products, 50 clinical trials
Top TAs: Ophthalmology, Cardiovascular, Infectious Diseases
Portfolio Health
Launch1 (13%)
Peak3 (38%)
LOE Approaching4 (50%)
8 total products
Therapeutic Area Focus
Ophthalmology
6 marketed
Cardiovascular
4 marketed
Marketed
Pipeline